AbbVie: Skyrizi And Rinvoq Growth Isn't Everything But It's A Lot (NYSE:ABBV)

Core Viewpoint - AbbVie (ABBV) stock has been trading in a range of $130 to $170 since 2022, primarily due to concerns regarding its future performance and market position [1]. Group 1: Company Overview - AbbVie has not been covered in detail for two years, indicating a potential gap in market analysis and investor interest [1]. - The stock's performance has been stagnant, reflecting investor apprehension about the company's growth prospects [1]. Group 2: Investment Strategy - The investment approach focuses on long-term holdings, aiming to maximize total return by purchasing stocks when they are undervalued relative to their intrinsic value [1]. - The strategy emphasizes lower volatility and higher income, aligning with the goal to match or exceed the S&P 500 returns over time [1].